Browsing Tag
Molecular residual disease
4 posts
Genentech secures first ctDNA MRD-guided therapy approval for Tecentriq in MIBC
A cancer drug win is only half the story. Roche and Natera are testing whether ctDNA can decide who truly needs treatment.
Abbott (ABT) closes $21bn Exact Sciences deal, making it the leader in U.S. cancer screening diagnostics
Abbott (ABT) closes its $21bn Exact Sciences acquisition, creating a $12bn+ diagnostics leader in cancer screening and precision oncology. Read the full analysis.
Exact Sciences (NASDAQ: EXAS) earnings show why Abbott moved now on a $21bn diagnostics acquisition
Exact Sciences delivered record 2025 results ahead of its Abbott acquisition. Find out why cash flow, screening scale, and timing matter now.
Natera boosts ctDNA and lymphoma detection capabilities through Foresight Diagnostics acquisition
Find out how Natera’s acquisition of Foresight Diagnostics could redefine ultra-sensitive cancer detection and reshape the future of MRD testing.